Lekoklar

Clarithromycin, the active ingredient in Lekoklar, is a macrolide antibiotic presented as an oral tablet for oral use. It treats bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, skin and soft‑tissue infections, and is used in combination regimens for Helicobacter pylori eradication in adult patients.

GNH USA supplies Lekoklar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clarithromycin is a macrolide antibiotic used to treat bacterial infections in various organ systems. - Community‑acquired pneumonia: eradicates the causative bacteria and improves respiratory function. - Acute bacterial sinusitis: reduces sinus inflammation by eliminating pathogenic microbes. - Skin and soft‑tissue infections: clears Staphylococcus and Streptococcus species from affected tissues. - Helicobacter pylori eradication (in combination therapy): contributes to bacterial clearance as part of a multi‑drug regimen.

Clarithromycin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools. - Abdominal pain: cramping or discomfort. - Taste disturbance: altered or metallic taste. - Headache: mild tension‑type headache. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or jaundice. - QT prolongation: cardiac arrhythmia risk. - Severe allergic reaction: anaphylaxis or angioedema. - Clostridioides difficile colitis: severe diarrhea with abdominal pain. - Stevens‑Johnson syndrome: mucocutaneous blistering. - Hematologic abnormalities: neutropenia or thrombocytopenia.

Before prescribing Lekoklar, clinicians should consider several safety factors. - Assess liver function: avoid use in patients with severe hepatic impairment. - Evaluate cardiac risk: caution in individuals with known QT prolongation or electrolyte disturbances. - Review drug history: avoid concurrent use with strong CYP3A4 inhibitors. - Monitor renal function: dose adjustment may be needed in severe renal impairment. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Clarithromycin interacts with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may cause toxic plasma levels. - Certain antiarrhythmics (e.g., amiodarone, sotalol): increase risk of QT prolongation. - Statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin): heightened risk of myopathy.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Theophylline: increased serum concentrations, watch for toxicity. - Oral hypoglycemics (e.g., sulfonylureas): potential hypoglycemia, monitor glucose. - Carbamazepine: reduced clarithromycin levels, assess efficacy. - Digoxin: possible increased levels, monitor cardiac signs.